Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin in HCC Patients Undergoing Liver Resection
NCT02650427Phase 1Completed
- Sponsor
- Inserm
- Start
- Feb 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sitagliptin in hepatocellular carcinoma (HCC), sponsored by Inserm. Primary endpoint: Adverse Events at 3 weeks. Started Feb 2016; status: completed.
02
Drugs
sitagliptin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02650427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650427.